Date: 13th February 2023

To,
The Secretary
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code – 532523

To,
The Secretary
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol – Biocon

Dear Sirs,

Certificate pursuant to SEBI Circular no. SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021

In terms of Chapter XVII of the SEBI Circular no. SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, on Operational Circular for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper, as amended from time to time, please find enclosed a quarterly certificate confirming the use of Commercial Paper proceeds and adherence to other listing conditions, for the quarter ended 31st December, 2022.

We request you to kindly take the above certificate on record.

Thanking you.

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776

Encl: As above
To,
The Secretary
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code – 532523

To,
The Secretary
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol - Biocon

REF NO: ISIN CODE: As Per Annexure I
Maturity Value of CP: As Per Annexure I
Maturity Date of CP: As Per Annexure I

With reference to the above-mentioned Commercial Paper issued by us, it is hereby certified that:

1. The CPs were issued for the purposes mentioned in Annexure I and the CP proceeds were utilized for purposes disclosed therein and the Company is in adherence to other listing conditions as mentioned in the application for listing.
2. The other conditions of the offer document and the CP issuance directions are adhered to.
3. The asset classification of fund-based facilities from bank/Financial Institutions continues to be "Standard"
4. There has been no material change in our financial status which may adversely affect the credit rating of the Commercial Paper.
5. The total issuance of CPs during the calendar year up to the quarter ended Dec 2022 was Rs. 2250 Crores.

For Biocon Limited

Indranil Sen
(Chief Financial Officer)

Date: 13th February 2023
Place: - Bangalore
<table>
<thead>
<tr>
<th>Issuer Name</th>
<th>Date of CP issue</th>
<th>ISIN No.</th>
<th>Maturity Value in Rs. Cr</th>
<th>Maturity Date of CP</th>
<th>Units</th>
<th>End Use of Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biocon Limited</td>
<td>23/11/2022</td>
<td>INE376CG14016</td>
<td>2250</td>
<td>22/02/2023</td>
<td>45000</td>
<td>General Corporate Purpose (mezzanine financing) covering equity investment/ loan into subsidiaries</td>
</tr>
</tbody>
</table>